1 McDonald ME,Bender DP.Endometrial cancer:obesity,genetics,and targeted agents[J].Obstet Gynecol Clin North Am,2019,46(1):89-105. 2 Cancer Genome Atlas Research Network,Kandoth C,Schultz N,et al.Integrated genomic characterization of endometrial carcinoma[J].Nature,2013,497(7447):67-73. 3 Drakes ML,Czerlanis CM,Stiff PJ.Immune checkpoint blockade in gynecologic cancers:state of affairs[J].Cancers(Basel),2020,12(11):3301. 4 Bruno A,Ferlazzo G,Albini A,et al.A think tank of TINK/TANKs:tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis[J].J Natl Cancer Inst,2014,106(8):200. 5 Carrega P,Morandi B,Costa R,et al.Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-)cells and display an impaired capability to kill tumor cells[J].Cancer,2008,112(4):863-875. 6 Bruno A,Bassani B,D’Urso DG,et al.Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic,decidual NK-like cells from patients with colorectal cancer[J].Faseb J,2018,32(10):5365-5377. 7 Tarazona R,Lopez-Sejas N,Guerrero B,et al.Current progress in NK cell biology and NK cell-based cancer immunotherapy[J].Cancer Immunol Immunother,2020,69(5):879-899. 8 Zhan L,Liu X,Zhang J,et al.Immune disorder in endometrial cancer:Immunosuppressive microenvironment,mechanisms of immune evasion and immunotherapy[J].Oncol Lett,2020,20(3):2075-2090. 9 Shreeve N,Depierreux D,Hawkes D,et al.The CD94/NKG2A inhibitory receptor educates uterine NK cells to optimize pregnancy outcomes in humans and mice[J].Immunity,2021,54(6):1231-1244. 10 Fukui A,Yokota M,Funamizu A,et al.Changes of NK cells in preeclampsia[J].Am J Reprod Immunol,2012,67(4):278-286. 11 Versluis M A.C,Marchal S,Plat A,et al.The prognostic benefit of tumour-infiltrating natural killer cells in endometrial cancer is dependent on concurrent overexpression of human leucocyte antigen-E in the tumour microenvironment[J].Eur J Cancer,2017,86:285-295. 12 Albini A,Bruno A,Noonan DM,et al.Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment:implications for immunotherapy[J].Front Immunol,2018,9:527. 13 Close HJ,Stead LF,Nsengimana J,et al.Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma[J].Clin Exp Immunol,2020,200(1):33-44. 14 Wang L,Zhuang T,Li F,et al.Fluorene-9-bisphenol inhibits epithelial-mesenchymal transition of human endometrial cancer Ishikawa cells by repressing TGF-β signaling pathway[J].Environ Sci Pollut Res Int,2019,26(26):27407-413. 15 Suh DH,Lee S,Park HS,et al.Medroxyprogesterone reverses tolerable dose Metformin-Induced inhibition of invasion via Matrix Metallopeptidase-9 and transforming growth factor-β1 in KLE endometrial cancer cells[J].J Clin Med,2020,9(11):3585. 16 Fionda C,Stabile H,Cerboni C,et al.Hitting more birds with a stone:impact of TGF-β on ILC activity in cancer[J].J Clin Med,2020,9(1):143. 17 Degos C,Heinemann M,Barrou J,et al.Endometrial tumor microenvironment alters human NK Cell recruitment,and resident NK Cell phenotype and function[J].Front Immunol,2019,10:877. 18 Chamoto K,Hatae R,Honjo T.Current issues and perspectives in PD-1 blockade cancer immunotherapy[J].Int J Clin Oncol,2020,25(5):790-800. 19 Pesce S,Belgrano V,Greppi M,et al.Different features of Tumor-Associated NK Cells in patients with low-grade or high-grade peritoneal carcinomatosis[J].Front Immunol[J],2019,10:1963. 20 Greppi M,Tabellini G,Patrizi O,et al.Strengthening the antiTumor NK Cell function for the treatment of ovarian cancer[J].Int J Mol Sci,2019,20(4):890. 21 Tumino N,Martini S,Munari E,et al.Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors:Functional analysis and expression of PD-1 receptor[J].Int J Cancer,2019,145(6):1660-1668. 22 Vari F,Arpon D,Keane C,et al.Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL[J].Blood,2018,131(16):1809-1819. 23 Post CCB,Westermann AM,Bosse T,et al.PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer[J].Crit Rev Oncol Hematol,2020,152:102973. 24 Lenhard M,Heublein S,Kunert-Keil C,et al.Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer[J].BMC Cancer,2013,13:616. 25 Scholz C,Heublein S,Lenhard M,et al.Glycodelin a is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients[J].BMC Res Notes,2012,5:551. 26 Lee CL,Vijayan M,Wang X,et al.Glycodelin-A stimulates the conversion of human peripheral blood CD16-CD56bright NK cell to a decidual NK cell-like phenotype[J].Hum Reprod,2019,34(4):689-701. 27 Ricciuti B,Leonardi GC,Puccetti P,et al.Targeting indoleamine-2,3-dioxygenase in cancer:Scientific rationale and clinical evidence[J].Pharmacol Ther,2019,196:105-116. 28 Ino K,Yoshida N,Kajiyama H,et al.Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer[J].Br J Cancer,2006,95(11):1555-1561. 29 Ino K,Yamamoto E,Shibata K,et al.Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer:its association with disease progression and survival[J].Clin Cancer Res,2008,14(8):2310-2317. 30 Yoshida N,Ino K,Ishida Y,et al.Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model[J].Clin Cancer Res,2008,14(22):7251-7259. 31 Liu W,Sun L,Zhang J,et al.The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer[J].Biosci Rep,2021,41(4):20202321. 32 Zhou WJ,Chang KK,Wu K,et al.Rapamycin synergizes with cisplatin in antiendometrial cancer activation by improving IL-27-stimulated cytotoxicity of NK Cells[J].Neoplasia,2018,20(1):69-79. 33 André P,Denis C,Soulas C,et al.Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells[J].Cell,2018,175(7):1731-1743. 34 Marofi F,F Abdul-Rasheed OF,Rahman HS,et al.CAR-NK cell in cancer immunotherapy;a promising frontier[J].Cancer Sci,2021,112(9):3427-3436. |